Undecylprodigiosin selectively induces apoptosis in human breast carcinoma cells independent of p53

Toxicology and Applied Pharmacology

Volumn 225, Issue 3, 2007, Pages 318-328

  Ho, Tsing Fen ^a,b   Ma, Chieh Ju ^a   Lu, Chien Hsing ^a,c   Tsai, Yo Ting ^a   Wei, Yu Hong ^d   Chang, Jo Shu ^e   Lai, Jun Kai ^a   Cheuh, Pin Ju ^a   Yeh, Chi Tai ^f   Tang, Pin Chi ^a   Tsai Chang, Jinghua ^g   Ko, Jiunn Liang ^g   Liu, Fu Shing ^c   Yen, Hungchen E ^a   Chang, Chia Che ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d YUAN ZE UNIVERSITY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^g CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Bcl 2 family; Breast cancer; p53; Poly (ADP ribose) polymerase (PARP); Undecylprodigiosin (UP); z VAD.fmk

Indexed keywords

CASPASE 9; PRODIGIOSIN; PROTEIN P53; UNCLASSIFIED DRUG; UNDECYLPRODIGIOSIN;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; NICK END LABELING;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; BREAST NEOPLASMS; CASPASE 9; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IN SITU NICK-END LABELING; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; POLY(ADP-RIBOSE) POLYMERASES; PRODIGIOSIN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SERRATIA MARCESCENS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

BACTERIA (MICROORGANISMS); SERRATIA; STREPTOMYCES;

EID: 36448934493     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.08.007     Document Type: Article

References (48)

1. Bae J., Leo C.P., Hsu S.Y., and Hsueh A.J.W. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J. Biol. Chem. 275 (2000) 25255-25261
2. Carlson R.W., Brown E., Burstein H.J., Gradishar W.J., Hudis C.A., Loprinzi C., Mamounas E.P., Perez E.A., Pritchard K., Ravdin P., Recht A., Somlo G., Theriault R.L., Winer E.P., and Wolff A.C. National Comprehensive Cancer Network. NCCN Task Force Report: adjuvant therapy for breast cancer. J. Natl. Compr. Cancer Netw. Suppl 1 (2006) S1-S26
3. Chang J.T., Chang G.C., Ko J.L., Liao H.Y., Liu H.J., Chen C.C., Su J.M., Lee H., and Sheu G.T. Induction of tubulin by Docetaxel is associated with p53 status in human non-small cell lung cancer cell lines. Int. J. Cancer 118 (2006) 317-325
4. Certo M., Moore V.D.G., Nishino M., Wei G., Korsmeyer S., Armstrong S.A., and Letai1 A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cells 9 (2006) 351-365
5. Chen E., and Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol. Cell. Biol. 10 (1990) 5502-5509
6. Chipuk J.E., and Green D.R. Dissecting p53-dependent apoptosis. Cell Death Differ. 13 (2006) 994-1002
7. Cory S., and Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev., Cancer 2 (2002) 647-656
8. Cory S., and Adams J.M. Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cells 8 (2005) 5-6
9. Coultas L., and Strasser A. The role of the Bcl-2 protein family in cancer. Semin. Cancer Biol. 13 (2003) 115-123
10. Decatris M.P., Sundar S., and O'Byrne K.J. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat. Rev. 4 (2004) 53-81
11. Evan G.I., and Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 411 (2001) 342-348
12. Fürstner A. Chemistry and biology of roseophilin and the prodigiosin alkaloids: a survey of the last 2500 years. Angew. Chem., Int. Ed. Engl. 42 (2003) 3582-3603
13. Galoneck H.L., and Hardwick J.M. Upgrading the BCL-2 network. Nat. Cell Biol. 8 (2006) 1317-1319
14. Germain M., Mathai J.P., McBride H.M., and Shore G.C. Endoplasmic reticulum BIK initiates DRP1-regulated remodelling of mitochondrial cristae during apoptosis. EMBO J. 24 (2005) 1546-1556
15. Han J., Goldstein L.A., Gastman B.R., and Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J. Biol. Chem. 281 (2006) 10153-10163
16. Han J., Goldstein L.A., Hou W., and Rabinowich H. Functional linkage between Noxa and Bim in mitochondrial apoptotic events. J. Biol. Chem. 282 (2007) 16223-16231
17. Hasuwa H., Kaseda K., Einarsdottir T., and Okabe M. Small interfering RNA and gene silencing in transgenic mice and rats. FEBS Lett. 532 (2002) 227-230
18. Igney F.H., and Krammer P.H. Death and anti-death: tumor resistance to apoptosis. Nat. Rev., Cancer 2 (2002) 277-288
19. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, CA. Cancer J. Clin. 57 (2007) 43-66
20. Jiang P., Du W., Heese K., and Wu M. The Bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis. Mol. Cell. Biol. 26 (2006) 9071-9082
21. Johnstone R.W., Ruefli A.A., and Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
22. Kataoka T., Magae J., Nariuchi H., Yamasaki M., and Nagai K. Enhancement by concanavalin A of the suppressive effect of prodigiosin 25-C on proliferation of murine splenocytes. J. Antibiot. (Tokyo) 45 (1992) 1303-1312
23. Kim H., Rafiuddin-Shah M., Tu H.C., Jeffers J.R., Zambetti G.P., Hsieh J.J., and Cheng E.H. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 8 (2006) 1348-1358
24. Kroemer G., and Reed J. Mitochondrial control of cell death. Nat. Med. 6 (2000) 513-519
25. Lazebnik Y.A., Kaufmann S.H., Desnoyers S., Poirier G.G., and Earnshaw W.C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371 (1994) 346-347
26. Mathai J.P., Germain M., Marcllus R.C., and Shore G.C. Induction and endoplasmic reticulum location of BIK/NBK in response to apoptotic signaling by E1A and p53. Oncogene 21 (2002) 2534-2544
27. Meng X.W., Lee S.H., and Kaufmann S.H. Apoptosis in the treatment of cancer: a promise kept?. Curr. Opin. Cell Biol. 18 (2006) 668-676
28. Metcalfe S., Ashley N., Chen Z., and Calne R.Y. Prodigiosin 25C: effect in in vitro models for T cell activation and T cell cycling and in vivo for rat heart allografts. Int. Arch. Allergy Immunol. 101 (1993) 132-135
29. Montaner B., Navarro S., Pique M., Vilaseca M., Martinell M., Giralt E., Gil J., and Pérez-Tomás R. Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines. Br. J. Pharmacol. 131 (2000) 583-593
30. Mortellaro A., Songia S., Gnocchi P., Ferrari M., Fornasiero C., D'Alessio R., Isetta A., Colotta F., and Golay J. New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-κB and AP-1 activation. J. Immunol. 162 (1999) 7102-7109
31. Nakamura A., Magae J., Tsuji R.F., Yamasaki M., and Nagai K. Suppression of cytotoxic T cell induction in vivo by prodigiosin 25-C. Transplantation 47 (1989) 1013-1016
32. Nakano K., and Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7 (2001) 683-694
33. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., and Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288 (2000) 1053-1058
34. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
35. Pérez-Tomás R., Montaner B., Llagostera E., and Soto-Cerrato V. The prodigiosins, proapoptotic drugs with anticancer properties. Biochem. Pharmacol. 66 (2003) 1447-1452
36. Peng X.H., Karna P., O'Regan R.M., Liu X., Naithani R., Moriarty R.M., Wood W.C., Lee H.Y., and Yang L. Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol. Pharmacol. 71 (2007) 101-111
37. Petersen O.W., Ronnov-Jessen L., Howlett A.R., and Bissell M.J. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 9064-9068
38. Sherr C.J. Principles of tumor suppression. Cell 116 (2004) 235-246
39. Song M.J., Bae J., Lee D.S., Kim C.H., Kim J.S., Kim S.W., and Hong S.I. Purification and characterization of prodigiosin produced by integrated bioreactor from Serratia sp. KH-95. J. Biosci. Bioeng. 101 (2006) 157-161
40. Songia S., Mortellaro A., Taverna S., Fornasiero C., Scheiber E.A., Erba E., Colotta F., Mantovani A., Isetta A.M., and Golay J. Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes. J. Immunol. 158 (1997) 3987-3995
41. Tsuji R.F., Yamamoto M., Nakamura A., Kataoka T., Magae J., Nagai K., and Yamasaki M. Selective immunosuppression of prodigiosin 25-C and FK506 in the murine immune system. J. Antibiot. (Tokyo) 43 (1990) 1293-1301
42. Tsuji R.F., Magae J., Yamashita M., Nagai K., and Yamasaki M. Immunomodulating properties of prodigiosin 25-C, an antibiotic which preferentially suppresses induction of cytotoxic T cells. J. Antibiot. (Tokyo) 45 (1992) 1295-1302
43. Wang C., Cusack J.J., Liu R., and Baldwin A.J. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med. 5 (1999) 412-417
44. Wei Y.H., and Chen W.C. Enhanced production of prodigiosin-like pigment from Serratia marcescens SMΔR by medium improvement and oil-supplementation strategies. J. Biosci. Bioeng. 99 (2005) 616-622
45. Wei Y.H., Yu W.J., and Chen W.C. Enhanced undecylprodigiosin production from Serratia marcescens SS-1 by medium formulation and amino-acid supplementation. J. Biosci. Bioeng. 100 (2005) 466-471
46. Williamson N.R., Fineran P.C., Leeper F.J., and Salmond G.P. The biosynthesis and regulation of bacterial prodiginines. Nat. Rev. Microbiol. 4 (2006) 887-899
47. Yang L., Cao Z., Yan H., and Wood W.C. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implications for cancer specific therapy. Cancer Res. 63 (2003) 6815-6824
48. Yu J., Zhang L., Hwang P.M., Kinzler K.W., and Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7 (2001) 673-682